for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Astellas Pharma Inc

4503.T

Latest Trade

1,530.00JPY

Change

8.00(+0.53%)

Volume

8,797,700

Today's Range

1,523.00

 - 

1,560.00

52 Week Range

1,356.00

 - 

2,026.50

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,522.00
Open
1,526.50
Volume
8,797,700
3M AVG Volume
109.66
Today's High
1,560.00
Today's Low
1,523.00
52 Week High
2,026.50
52 Week Low
1,356.00
Shares Out (MIL)
1,886.11
Market Cap (MIL)
2,889,900.00
Forward P/E
14.80
Dividend (Yield %)
2.48

Next Event

Dividend For 4503.T - 20.0000 JPY

Latest Developments

More

EU Medicines Agency Says CHMP Recommends Granting Marketing Authorisation For AstraZeneca's Drug Qtrilmet

Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare

Astellas Pharma Says Japan's Ministry Of Health, Labour And Welfare Approved Evrenzo(Roxadustat)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Astellas Pharma Inc

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

Industry

Major Drugs

Contact Info

2-5-1, Nihombashihon-cho

+81.3.32443000

https://www.astellas.com/jp/

Executive Leadership

Yoshihiko Hatanaka

Chairman of the Board, Chairman of the Board of Directors, Representative Director

Kenji Yasukawa

President, Chief Executive Officer, Representative Director

Nobuaki Tanaka

Senior Executive Officer, Chief Director of Sales

Akihiko Iwai

Senior Executive Officer, Chief Director of Research

Atsushi Kamide

Senior Executive Officer, Director of External Affairs

Key Stats

2.27 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

1.3K

2018

1.3K

2019

1.3K

2020(E)

1.2K
EPS (JPY)

2017

103.690

2018

81.110

2019

115.050

2020(E)

103.412
Price To Earnings (TTM)
12.97
Price To Sales (TTM)
2.20
Price To Book (MRQ)
2.31
Price To Cash Flow (TTM)
9.94
Total Debt To Equity (MRQ)
13.85
LT Debt To Equity (MRQ)
10.37
Return on Investment (TTM)
15.65
Return on Equity (TTM)
11.93

Latest News

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million (97 million pounds) to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department...

Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications, the U.S. Justice Department said on Thursday.

Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc <PFE.N> and Astellas Pharma Inc <4503.T> said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment...

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms

* FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31

BRIEF-Astellas Says To Cancel Treasury Stock Equivalent To 4.3 Percent Of Shares Outstanding

* ASTELLAS SAYS TO CANCEL TREASURY STOCK EQUIVALENT TO 4.3 PERCENT OF SHARES OUTSTANDING Further company coverage: (Reporting By Chris Gallagher)

BRIEF-Astellas Pharma Submits NDA For Approval Of Gilteritinib

* ASTELLAS SUBMITS NEW DRUG APPLICATIONS FOR APPROVAL OF GILTERITINIB FOR THE TREATMENT OF FLT3MUT+ RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement

* PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas

* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS

BRIEF- Astellas Pharma completes share repurchase

* Says it completes repurchase of 39.6 million shares of its common stock, for 60 billion yen in total, during period from Feb. 1 to March 23

BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi

* U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

BRIEF-Astellas Pharma acquires Universal Cells

* Says it has acquired Universal Cells Inc., and will pay up to $102.5 million of upfront and milestones to acquire 100 percent ownership of Universal Cells depending on achievement of certain specified clinical milestones

BRIEF-Astellas acquires Universal Cells Inc

* ASTELLAS WILL PAY UP TO $102.5 MILLION OF UPFRONT AND MILESTONES TO ACQUIRE 100 PERCENT OWNERSHIP OF UNIVERSAL CELLS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up